[HTML][HTML] Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
Annals of Oncology, 2019 - Elsevier
Background Treatment with immune checkpoint blockade (ICB) with agents such as anti-
programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/or …
programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/or …
[HTML][HTML] Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
TA Chan, M Yarchoan, E Jaffee, C Swanton… - Annals of …, 2019 - ncbi.nlm.nih.gov
Background Treatment with immune checkpoint blockade (ICB) with agents such as anti-
programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/or …
programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/or …
[PDF][PDF] Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
TA Chan, M Yarchoan, E Jaffee, C Swanton… - Annals of …, 2019 - scholar.archive.org
Background: Treatment with immune checkpoint blockade (ICB) with agents such as anti-
programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/or …
programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/or …
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.
TA Chan, M Yarchoan, E Jaffee, C Swanton… - Annals of oncology …, 2019 - folia.unifr.ch
Materials and methods In this review, we outline the evolution of TMB as a biomarker in
oncology, delineate how TMB can be applied in the clinic, discuss current limitations as a …
oncology, delineate how TMB can be applied in the clinic, discuss current limitations as a …
[PDF][PDF] Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
TA Chan, M Yarchoan, E Jaffee, C Swanton… - Annals of …, 2019 - core.ac.uk
Background: Treatment with immune checkpoint blockade (ICB) with agents such as anti-
programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/or …
programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/or …
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
TA Chan, M Yarchoan, E Jaffee, C Swanton… - Annals of …, 2019 - discovery.ucl.ac.uk
Background: Treatment with immune checkpoint blockade (ICB) with agents such as anti-
programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/or …
programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/or …
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
TA Chan, M Yarchoan, E Jaffee, C Swanton… - Annals of …, 2019 - annalsofoncology.org
Background Treatment with immune checkpoint blockade (ICB) with agents such as anti-
programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/or …
programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/or …
[PDF][PDF] Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
TA Chan, M Yarchoan, E Jaffee, C Swanton… - 2019 - crick.figshare.com
Background: Treatment with immune checkpoint blockade (ICB) with agents such as anti-
programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/or …
programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/or …
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.
TA Chan, M Yarchoan, E Jaffee, C Swanton… - Annals of Oncology …, 2019 - europepmc.org
Background Treatment with immune checkpoint blockade (ICB) with agents such as anti-
programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/or …
programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/or …
[PDF][PDF] Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
TA Chan, M Yarchoan, E Jaffee, C Swanton… - Annals of …, 2019 - scienceopen.com
Background: Treatment with immune checkpoint blockade (ICB) with agents such as anti-
programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/or …
programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/or …